Clinical research study of a dietary supplement for patients with early-stage Parkinson's Disease
"Early-stage Parkinson's Disease: Oral inosine for newly diagnosed patients"
30 or older at time of PD diagnosis
Healthy Volunteers:
Parkinson's Disease, PD, DaT scan, Early-onset, Tremor, Dopamine, Imaging, Parkinson, Rigidity, Bradykinesia, Nerves, Neurology, Brain
Phase 3 - Drug Study
270 Participants
This study is trying to find out if a drug called oral inosine given for two years to recently diagnosed Parkinson's Disease patients could slow the decline of the disease.
This study requires
  • About 14 visits over about 28 months to the UC Davis Neurology Clinic

  • Take drug/placebo two to three times per day

  • Brain scan, blood draws, urine collection, ECGs, and questionnaires at study visits

Who can participate

Adults who were age 30 or older at time of Parkinson's diagnosis, and who do not currently have disability requiring dopaminergic therapy.

Benefits and risks of participating
There is no guarantee of benefit from taking part in the study, but if you receive the study drug, it is possible that your Parkinson’s may progress more slowly than typical.

You may get an upset stomach from the study drug, and there is a small risk of getting kidney stones or gout.
Compensation is provided for time and effort.
PDF Docs
Patient Brochure
What to expect if you participate
Study duration and period
You will come to the UC Davis Neurology clinic about 14 times during the study, over a period of a little more than two years. Each visit will take from 3-6 hours.
Recruitment period
From Dec. 1, 2016 to Dec. 1, 2019
Siobhan Vasquez

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview